In melanoma, DDR2 stimulates tumor proliferation through the MAP kinase pathway [55], while in lung adenocarcinoma, it enhances cell growth via the focal adhesion kinase (FAK) signaling pathway [30]. Here, PTK2 is linked to neoplasm.